GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » Long-Term Debt

Harbin Medisan Pharmaceutical Co (SZSE:002900) Long-Term Debt : ¥83 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co Long-Term Debt?

Harbin Medisan Pharmaceutical Co's Long-Term Debt for the quarter that ended in Mar. 2024 was ¥83 Mil.

Harbin Medisan Pharmaceutical Co's quarterly Long-Term Debt increased from Sep. 2023 (¥211 Mil) to Dec. 2023 (¥230 Mil) but then declined from Dec. 2023 (¥230 Mil) to Mar. 2024 (¥83 Mil).

Harbin Medisan Pharmaceutical Co's annual Long-Term Debt increased from Dec. 2021 (¥205 Mil) to Dec. 2022 (¥418 Mil) but then declined from Dec. 2022 (¥418 Mil) to Dec. 2023 (¥230 Mil).


Harbin Medisan Pharmaceutical Co Long-Term Debt Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co Long-Term Debt Chart

Harbin Medisan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 204.84 417.79 229.83

Harbin Medisan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 421.10 424.48 210.96 229.83 82.63

Harbin Medisan Pharmaceutical Co  (SZSE:002900) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Harbin Medisan Pharmaceutical Co Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025
Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.
Executives
Fan Qing Ji Executives
Zhao Qing Fu Directors, Directors, and Executives
Liang Yan Fei Directors, executives
Yao Fa Xiang Executives
Wang Ming Xin Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines